# GSK Agrees to Acquire Nuvalent for $10.6 Billion to Add Two Late-Stage Lung Cancer Inhibitors

> ma · REPORTED · 2026-06-09

GSK announced a $10.6 billion all-cash acquisition of Nuvalent at $124 per share, a 40% premium, securing two potential best-in-class next-generation ROS1 and ALK inhibitors — zidesamtinib and neladalkib — both currently under FDA review with 2026 approval decisions expected. The deal is GSK's largest acquisition in over a decade and accelerates its entry into precision lung cancer oncology.

About GSK: GSK is a global biopharma company developing vaccines, specialty medicines, and general medicines across oncology, immunology, and infectious diseases.

- Company: GSK
- Sector: therapeutics
- Primary source: https://www.sec.gov/Archives/edgar/data/0001861560/000119312526262950/d137459dex991.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.